Could immune reset with donor CAR T-Cells tame lupus?
NCT ID NCT07410377
First seen Feb 18, 2026 · Last updated Apr 30, 2026 · Updated 11 times
Summary
This early-phase study tests a universal (donor-derived) CAR T-cell therapy called QT-019C in 15 adults with lupus or inflammatory myositis that has not responded to standard treatments. The therapy targets two immune-cell markers (CD19 and BCMA) to reset the faulty immune system. The main goals are to check safety and see if it can reduce disease activity without needing lifelong medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.